Logo do repositório
 
Publicação

GLP-1 receptor agonists for obesity: eligibility across 99 countries

2026-02-06Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorYoo, Sang Gune K.
dc.contributor.authorTeufel, Felix
dc.contributor.authorTheilmann, Michaela
dc.contributor.authorSi, Yajuan
dc.contributor.authorToure, Elhadji A.
dc.contributor.authorAryal, Krishna
dc.contributor.authorBärnighausen, Till
dc.contributor.authorBait, Abdul
dc.contributor.authorBarreto, Marta
dc.contributor.authorBovet, Pascal
dc.contributor.authorBrant, Luisa C.C.
dc.contributor.authorCuschieri, Sarah
dc.contributor.authorDamasceno, Albertino
dc.contributor.authorFarzadfar, Farshad
dc.contributor.authorFawwad, Asher
dc.contributor.authorGeldsetzer, Pascal
dc.contributor.authorHambleton, Ian R.
dc.contributor.authorHouehanou, Corine
dc.contributor.authorHowitt, Christina
dc.contributor.authorJ Rgensen, Jutta
dc.contributor.authorGonzález-Rivas, Juan P.
dc.contributor.authorLabadarios, Demetre
dc.contributor.authorMarcus, Maja
dc.contributor.authorMartins, João
dc.contributor.authorMwalim, Omar
dc.contributor.authorNieto-Martínez, Ramfis
dc.contributor.authorOdili, Augustine N.
dc.contributor.authorOrazumbekova, Binur
dc.contributor.authorPerman, Gastón
dc.contributor.authorQuesnel-Crooks, Sarah
dc.contributor.authorMoghaddam, Sahar Saeedi
dc.contributor.authorSewpal, Ronel
dc.contributor.authorSousa-Uva, Mafalda
dc.contributor.authorSulola, Mubarak A.
dc.contributor.authorVenkataraman, Kavita
dc.contributor.authorVollmer, Sebastian
dc.contributor.authorXueling, Sim
dc.contributor.authorAtun, Rifat
dc.contributor.authorBanegas, José R.
dc.contributor.authorFranco, Juan V. A.
dc.contributor.authorArnott, Clare
dc.contributor.authorChandiwana, Nomathemba
dc.contributor.authorHuffman, Mark D.
dc.contributor.authorDavies, Justine
dc.contributor.authorAli, Mohammed K.
dc.contributor.authorFlood, David
dc.contributor.authorManne-Goehler, Jennifer
dc.date.accessioned2026-09-28T15:16:38Z
dc.date.available2026-09-28T15:16:38Z
dc.date.issued2026-02-06
dc.descriptionErratum in Correction to Lancet Diabetes & Endocrinology 2026; 14: 105-08. Lancet Diabetes Endocrinol. 2026 Mar;14(3):e6. doi: 10.1016/S2213-8587(25)00426-7. Epub 2026 Jan 12.
dc.descriptionCorrespondence
dc.description.abstractWe analysed pooled, individual participant data from nationally representative, cross-sectional household health surveys conducted in 99 countries between 2008 and 2021 (appendix pp 2–67). Our sample comprised non-pregnant individuals aged 25–64 years with an available diabetes biomarker, blood pressure measurement, and BMI measurement, as well as complete data on hypertension and diabetes diagnoses (appendix pp 69–75). Eligibility for GLP-1 receptor agonists was determined by applying the inclusion criteria from key randomised clinical trials.3,4 Individuals were defined as eligible for GLP-1 receptor agonists for weight management if they had a BMI of 30 kg/m2 or more or a BMI of 27 kg/m2 or more with hypertension or diabetes, or both—two common weight-related comorbidities. Hypertension was defined based on measured blood pressure and diabetes was defined based on glycaemic markers (HbA1c and plasma glucose). We did not consider other obesity-related comorbidities, such as obstructive sleep apnoea or cardiovascular disease, because data were not consistently available across surveys. For countries in the south, east, and southeast Asian region, we adjusted the eligibility to a BMI of 28 kg/m2 or more or a BMI of 24 kg/m2 or more with hypertension or diabetes, or both, in line with regionally based clinical trials.6 All statistical analyses included sampling weights that we rescaled in proportion to the countries’ population sizes. This study was deemed exempt from regulation by the institutional review board at the University of Michigan (Ann Arbor, MI, USA; HUM00201307).eng
dc.identifier.citationLancet Diabetes Endocrinol. 2026 Feb;14(2):105-108. doi: 10.1016/S2213-8587(25)00356-0
dc.identifier.doihttps://doi.org/10.1016/S2213-8587(25)00356-0
dc.identifier.eissn2213-8595
dc.identifier.issn2213-8587
dc.identifier.pmid41519598
dc.identifier.urihttp://hdl.handle.net/10400.18/11348
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/abs/pii/S2213858725003560?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectGLP-1 Receptor Agonists
dc.subjectObesity
dc.subjectObesity Treatment
dc.subjectObesity prevalence
dc.subjectHealthcare Access
dc.subjectHealth Equity
dc.subjectGlobal health
dc.subjectDeterminantes da saúde e da doença
dc.subjectCuidados de saúde
dc.subjectEstados de saúde e da doença
dc.subjectINSEF
dc.titleGLP-1 receptor agonists for obesity: eligibility across 99 countrieseng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage108
oaire.citation.issue2
oaire.citation.startPage105
oaire.citation.titleThe Lancet Diabetes & Endocrinology
oaire.citation.volume14
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 2 de 2
Miniatura
Nome:
PIIS2213858725004267.pdf
Tamanho:
33.27 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Miniatura
Nome:
PIIS2213858725003560.pdf
Tamanho:
178.49 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais